NCT01239394已完成2 期
Phase II Trial Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 43
- 试验地点
- 3
- 主要终点
- Efficacy: Complete Response Rate (CRR)
研究概览
简要总结
Ofatumumab is a drug that works by attaching to the CD20 molecule found on the surface of cancerous B cells, and then triggering the death of those cells. It is approved by the FDA for treatment of another B-cell cancer, chronic lymphocytic leukemia, and also has evidence of success in people who's B-cell lymphomas have relapsed after initial treatments. In this research study we are looking to see if ofatumumab is effective and safe in treating previously untreated B-cell NHL.
详细描述
- Participants will receive ofatumumab once a week for 8 weeks by intravenous infusion (Days 1, 8, 15, 22, 29, 36, 43, and 50).
- Participants will be seen weekly during the 8 week treatment period and will have the following tests and procedures performed: Blood tests, performance status and physical examination.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed indolent CD20+B-cell NHL of the following histologies: follicular lymphoma, grades 1-2; Marginal zone lymphoma (extranodal, nodal or splenic); small lymphocytic lymphoma; low-grade B-cell lymphoma not otherwise specified with CD20+ expression
- •Measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension as 20mm or greater CT scan or MRI
- •No previous chemotherapy, antibody therapy or radioimmunotherapy for this disease. Patients previously treated with external beam radiation alone are eligible
- •18 years of age or older
- •Life expectancy of greater than 3 months
- •ECOG Performance status of 0, 1 or 2
- •Organ function as described in the protocol
- •Women of child-bearing potential and men must agree so use adequate contraception prior to study entry and for the duration of study participation
排除标准
- •Prior chemotherapy, antibody therapy or radioimmunotherapy for lymphoma
- •Participants may not be receiving any other investigational agent
- •Participants with known brain metastases
- •History of allergic reactions attributed to compounds of similar chemical or biologic composition to ofatumumab
- •Prior exposure to ofatumumab or other targeted anti-CD20 therapies including rituximab
- •Known HIV positivity
- •Positive serology for Hepatitis B
- •Positive serology for Hepatitis C
- •Participants who are candidates for curative radiotherapy, unless radiation therapy is considered too toxic (as in abdominal disease), or is refused by the patient
- •New York Heart Association Classification III of IV heart disease
- •Uncontrolled intercurrent illness including, but not limited to ongoing or active infection that is not optimally treated with antibiotics, unstable angina pectoris, or psychiatric illness/social situations that would limit compliance with study requirements
- •Pregnant or breastfeeding women
- •History of a different malignancy are ineligible except for the following circumstances: Individuals with a history of other malignancy are eligible if they have been disease-free for at least one year and are deemed by the investigator to be at low risk for recurrence of that malignancy. Individuals with the following cancers are eligible even if diagnosed and treated within the past 1 year: localized prostate cancer, prostate cancer with elevated PSA but no measurable disease on CT scans or bone scan, cervical cancer in situ, breast ductal carcinoma in situ and non-melanoma skin cancers.
研究组 & 干预措施
ofatumumab
Other
single-arm, open-label, interventional
干预措施: ofatumumab (Drug)
结局指标
主要结局
Efficacy: Complete Response Rate (CRR)
时间窗: 1-month post-treatment
Evaluate clinical efficacy of ofatumumab in previously untreated indolent B-cell lymphomas, as measured by complete response rate (CRR). Complete response = all previously enlarged fluorodeoxyglucose (FDG)-avid or positron emission tomography (PET)-positive lymph nodes regressed to normal size (\<=1.5 cm in greatest diameter)
次要结局
- Progression-free Survival (PFS)(12 months)
- Overall Response Rate (ORR)(1-month post-treatment)
- Toxicity: Infusion Reactions, Grade 3-4 Infections, and Neutropenia(2 years)
研究者
Jeremy Abramson, MD
Director, Lymphoma Program
Massachusetts General Hospital
研究点 (3)
Loading locations...
相似试验
已完成
2 期
Ofatumumab-based Induction Chemoimmunotherapy in Previously Untreated Patients With CLL/SLLSmall Lymphocytic LymphomaCLL (Chronic Lymphocytic Leukemia)NCT01145209National Heart, Lung, and Blood Institute (NHLBI)32
已完成
2 期
Ofatumumab With IVAC Salvage Chemotherapy in Diffuse Large B Cell Lymphoma PatientsDiffuse Large B Cell LymphomaNCT01481272Polish Lymphoma Research Group77
已完成
2 期
Ofatumumab as Front-Line Therapy in Treating Elderly Participants With Chronic Lymphocytic LeukemiaChronic Lymphocytic LeukemiaNCT01444716M.D. Anderson Cancer Center34
已完成
2 期
Ofatumumab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin LymphomaLymphomaNCT01190449Alliance for Clinical Trials in Oncology51
已完成
1 期
Ofatumumab Cardiac Repolarization (QTc) Study in Fludarabine-Refractory Chronic Lymphocytic Leukemia SubjectsLeukaemia, Lymphocytic, ChronicNCT01110031GlaxoSmithKline12